welcome to oneGRAVESvoice- a positively charged Graves' disease and thyroid eye disease community.
- join today!
- log in
The committee will discuss biologics license application (BLA) 761143, teprotumumab solution for intravenous use, submitted by Horizon Pharma Ireland, Ltd., proposed for the treatment of active thyroid eye disease.
The public participation information has been changed for the December 13, 2019 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee. The deadline for making formal oral presentation requests has been changed from Tuesday, November 26, 2019 to Monday, December 2, 2019. The deadline for submitting electronic or written comments to be provided to the committee has been changed from Wednesday, December 4, 2019 to Monday, December 9, 2019.
Date & Time:
December 13, 2019
8:00 AM to 4:00 PM
FDA White Oak Campus
10903 New Hampshire Avenue
Building 31 Conference Center
The Great Room (Rm. 1503)
Silver Spring, Maryland, United States
This event has ended.
Scheie Eye Institute – Thyroid Eye Disease ProgramScheie’s Thyroid Eye Disease Program o...
Common Immunosuppressive Monotherapy for Graves’ Ophthalmopathy: A Meta-AnalysisBackground: Several immunosuppressive t...
Sandy Zhang-Nunes, MDSandy Zhang-Nunes, MD, earned her underg...
The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves’ Ophthalmopathy PatientsPurpose: The purpose of this study is t...
Management of Patients With Graves’ Orbitopathy: Initial Assessment, Management Outside Specialised Centres and Re...Graves' orbitopathy (GO) is uncommon, bu...
Orbital Decompression for Thyroid Eye Disease: Methods, Outcomes, and ComplicationsPurpose: To determine the safety and ef...
Breakthrough Treatment for Thyroid Eye DiseaseFor those with severe inflammation from ...